REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Executive Performance Protocol

Cognitive Enhancementintermediate
25
Share
Peptides

3

Avg Daily mcg

3,900

Level

intermediate

Added

May 16, 2026

Overview

The Executive Performance Protocol is an intermediate-level cognitive enhancement stack designed for professionals, entrepreneurs, and knowledge workers who demand sustained mental clarity, emotional resilience, and neuroprotective support. This three-peptide combination targets multiple cognitive pathways simultaneously—attention and working memory, stress adaptation, and long-term neuronal health. Semax at 900mcg daily is a synthetic analogue of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia. It powerfully upregulates Brain-Derived Neurotrophic Factor (BDNF), the key neurotrophin responsible for neuroplasticity, learning, and long-term memory formation. Semax enhances dopaminergic and serotonergic neurotransmission, improving focus, motivation, and mental stamina without the jitteriness or crash of stimulants. Clinical research has demonstrated its efficacy in improving attention, cognitive processing speed, and recovery from mental fatigue. At 900mcg, this represents a robust nootropic dose. Selank at 500mcg daily is an anxiolytic peptide based on tuftsin that modulates GABA activity and reduces excessive stress signaling. It provides calm, clear-headed focus by reducing the cognitive interference caused by anxiety and rumination. Selank also enhances memory encoding and emotional regulation, making it particularly valuable during high-pressure decision-making. Its immunomodulatory properties provide an additional layer of support for executives under chronic stress. Epithalon at 5000mcg every other day provides long-term neuroprotection by maintaining telomere integrity in neuronal cells and supporting healthy pineal function. The pineal gland regulates not only sleep but also broader neuroendocrine rhythms essential for sustained cognitive performance. Epithalon ensures that the performance gains from Semax and Selank are built on a foundation of cellular longevity. Protocol Notes: Semax and Selank are administered intranasally for rapid CNS absorption, ideally in the morning or before demanding cognitive work. Epithalon is injected subcutaneously on alternating days. This stack is ideal for professionals managing heavy cognitive loads, students during intensive study periods, or anyone seeking reliable mental performance without stimulant dependency. Typical cycles are 30-60 days with periodic breaks.

Dosing Protocol

900 mcg

per dose

500 mcg

per dose

Epithalon

Every other day

Read more about Epithalon →

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.